×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

Fernando Garces

Senior Scientist
Therapeutic Discovery

Fernando is a recipient of the 2015 Scripps CHAVI-ID Young Investigator Award for outstanding contributions to the development of an anti-HIV-1 vaccine to elicit broadly neutralizing antibodies. His research career started when he was awarded an international PhD fellowship to join the University of Barcelona, Spain, in 2004. After finishing his PhD in Biotechnology, he moved to the ICR in London, UK, where he started his postdoctoral research on proteins involved in DNA Repair and the molecular mechanisms that made their application as oncologic targets possible. In 2012, he joined Professor Ian Wilson’s lab at TSRI, to understand the molecular details that mediate the antibody-protein recognition such as HIV-Env gp160. In 2016, Fernando joined the Molecular Engineering group at Amgen in San Francisco, to elucidate molecular structures of antibodies with exciting cardiovascular and oncologic targets. In early 2017, Fernando moved to the Biologics Optimization group at Amgen in Thousand Oaks, where he leads a team of Protein Engineers focused on the design of a new generation of multi-specific antibodies with high therapeutic value.

Featured Publications

Garces F, Mohr C, Zhang L, Huang CS, Chen Q, King C, Xu C, Wang Z. “Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab)”, Cell Rep. 2020 Feb 11;30(6):1714-1723 https://pubmed.ncbi.nlm.nih.gov/32049005/

Garces F, Lee JH, de Val N, de la Pena AT, Kong L, Puchades C, Hua Y, Stanfield RL, Burton DR, Moore JP, Sanders RW, Ward AB, Wilson IA “Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans” Immunity. 2015 Dec 15;43(6):1053-63. https://pubmed.ncbi.nlm.nih.gov/26682982/

Garces F, Sok D, Kong L, McBride R, Kim HJ, Saye-Francisco KF, Julien JP, Hua Y, Cupo A, Moore JP, Paulson JC, Ward AB, Burton DR, Wilson IA. "Structural evolution of glycan recognition by a family of exceptionally potent broadly neutralizing HIV antibodies." Cell, (2014) 25;159(1):69-79 Featured in Views & News https://pubmed.ncbi.nlm.nih.gov/25259921/

Garces F, Pearl LH, Oliver AW. The structural basis of substrate recognition by mammalian polynucleotide kinase 3’ phosphatase.” Mol Cell, (2011) Nov 4;44, 3, 385-396 https://pubmed.ncbi.nlm.nih.gov/22055185/

Education

Postdoctoral Research Fellowship, The Scripps Research Institute, San Diego, US                   
Postdoctoral Research Fellowship, The Institute of Cancer Research, London, UK
Ph.D., Biotechnology, University of Barcelona, Barcelona, Spain
M.S., Biotechnology, University of Barcelona, Barcelona, Spain
B.S., Microbiology, Portuguese Catholic University, Porto, Portugal